Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy.

Long KK, O'Shea KM, Khairallah RJ, Howell K, Paushkin S, Chen KS, Cote SM, Webster MT, Stains JP, Treece E, Buckler A, Donovan A.

Hum Mol Genet. 2019 Apr 1;28(7):1076-1089. doi: 10.1093/hmg/ddy382.

2.

Bone loss in survival motor neuron (Smn(-/-) SMN2) genetic mouse model of spinal muscular atrophy.

Shanmugarajan S, Tsuruga E, Swoboda KJ, Maria BL, Ries WL, Reddy SV.

J Pathol. 2009 Sep;219(1):52-60. doi: 10.1002/path.2566.

3.

Neonatal spinal muscular atrophy type 1 with bone fractures and heart defect.

Vaidla E, Talvik I, Kulla A, Sibul H, Maasalu K, Metsvaht T, Piirsoo A, Talvik T.

J Child Neurol. 2007 Jan;22(1):67-70.

PMID:
17608308
4.

Neonatal spinal muscular atrophy with multiple contractures, bone fractures, respiratory insufficiency and 5q13 deletion.

García-Cabezas MA, García-Alix A, Martín Y, Gutiérrez M, Hernández C, Rodríguez JI, Morales C.

Acta Neuropathol. 2004 May;107(5):475-8. Epub 2004 Feb 13.

PMID:
14968368

Supplemental Content

Loading ...
Support Center